Bcwm LLC Takes Position in Pfizer Inc. (NYSE:PFE)

Bcwm LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE) in the 2nd quarter, Holdings Channel reports. The fund bought 170,885 shares of the biopharmaceutical company’s stock, valued at approximately $4,781,000. Pfizer makes up 1.7% of Bcwm LLC’s portfolio, making the stock its 25th biggest position.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Cantor Fitzgerald Investment Advisors L.P. bought a new position in shares of Pfizer during the fourth quarter worth approximately $16,166,000. LGT Group Foundation lifted its holdings in shares of Pfizer by 2.5% during the second quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock worth $20,786,000 after buying an additional 18,274 shares in the last quarter. ORG Partners LLC boosted its position in shares of Pfizer by 1,729.9% in the second quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock valued at $1,327,000 after acquiring an additional 44,458 shares during the period. Kempner Capital Management Inc. bought a new position in Pfizer during the first quarter worth about $2,439,000. Finally, Leo Wealth LLC bought a new position in Pfizer during the fourth quarter worth about $2,171,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on PFE. Wells Fargo & Company increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. UBS Group upped their target price on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Price Performance

Pfizer stock opened at $29.27 on Monday. The stock has a 50-day moving average price of $29.21 and a two-hundred day moving average price of $28.13. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $34.42. The company has a market capitalization of $165.86 billion, a PE ratio of -487.83, a P/E/G ratio of 1.04 and a beta of 0.68. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same quarter last year, the business earned $0.67 EPS. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were issued a dividend of $0.42 per share. The ex-dividend date of this dividend was Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.74%. Pfizer’s payout ratio is -2,800.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.